NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a distribution deal for its SelectMDx for Prostate Cancer test in Spain with pharmaceutical company Ferrer.

Under the terms of the five-year exclusive deal, 10 Ferrer sales representatives will sell SelectMDx directly to 1,000 urologists in Spain. Samples will be sent to MDxHealth's laboratory in Nijmegen, the Netherlands for analysis. The agreement takes effect in January 2018.

Additional terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.